JPRN-UMIN000014671招募中未知
Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer - Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer
Radiation Oncology, Tokai University Hachioji Hospital0 个研究点目标入组 20 人开始时间: 2014年7月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 80years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Patients who have had any other cancer within the past 5 years 2)Patients who have uncontrollable diabetes mellitus 3)Patients who have serious comorbidities such as collagen disease, heart disease, interstitial pneumonia, liver cirrhosis 4)patients who have a psychological problem 5)patients who had previously received pelvic irradiation 6)patients who had previously received pelvic surgery 7)patients who had previously received TURP, orchiectomy, or HIFU 8)patients who had previously received chemotherapy for prostate cancer 9)patients who have Crohn's disease or ulcerative colitis 10)patients who require concomitant anticoagulant therapy 11)IPSS at registration>=20
研究者
相似试验
终止
不适用
Stereotactic Hypofractionated body radiosurgery for Oligometastatic Renal cell Tumours upfront, with Systemic Targeted agents On ProgressioOligometastatic Renal Cell CancerCancer - KidneyRenal and Urogenital - Other renal and urogenital disordersACTRN12615000330549Peter MacCallum Cancer Centre30
终止
2 期
Study to assess the neurological and cognitive effects of using Hypofractionated Stereotactic Radiotherapy used to treat multiple (3-10) brain metastases.eurocognitive impairmentNeurocognitive impairmentCancer - Any cancerCancer - BrainACTRN12615001202550Icon Cancer Foundation30
进行中（未招募）
1 期
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trialCTIS2024-513207-13-00Institut De Cancerologie De L Ouest96
已完成
不适用
Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cmNon small cell lung cancer10038666Lung cancerNL-OMON39053ederlands Kanker Instituut15
进行中（未招募）
不适用
Combined stereotactic radiotherapy and conventional fractionation in stage II and II lungcancer.SCLC stage III or inoperable stage IIMedDRA version: 14.1Level: PTClassification code 10062041Term: Lung infiltration malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10023779Term: Large cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025036Term: Lung adenocarcinoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10062042Term: Lung neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029520Term: Non-small cell lung cancer stage IIIASystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025082Term: Lung disorderSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: PTClassification code 10025031Term: Lung adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025069Term: Lung carcinoma cell type unspecified stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10001250Term: Adenosquamous cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (inclEUCTR2012-002392-33-NLKI-AV